Meningococcal Factor H-binding Protein Variants Expressed by Epidemic Capsular Group A, W-135, and X Strains from Africa

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2009 Mar 24

PMID 19302008

Citations 42

Authors

P T Beernink

D A Caugant

J A Welsch

O Koeberling

D M Granoff

Affiliations

Soon will be listed here.

Abstract

Background: Meningococcal epidemics in Africa are generally caused by capsular group A strains, but W-135 or X strains also cause epidemics in this region. Factor H-binding protein (fHbp) is a novel antigen being investigated for use in group B vaccines. Little is known about fHbp in strains from other capsular groups.

Methods: We investigated fHbp in 35 group A, W-135, and X strains from Africa.

Results: The 22 group A isolates, which included each of the sequence types (STs) responsible for epidemics since 1963, and 4 group X and 3 group W-135 isolates from recent epidemics had genes encoding fHbp in antigenic variant group 1. The remaining 6 W-135 isolates had fHbp variant 2. Within each fHbp variant group, there was 92%-100% amino acid identity, and the proteins expressed conserved epitopes recognized by bactericidal monoclonal antibodies. Serum samples obtained from mice vaccinated with native outer membrane vesicle vaccines from mutants engineered to express fHbp variants had broad bactericidal activity against group A, W-135, or X strains.

Conclusions: Despite extensive natural exposure of the African population, fHbp is conserved among African strains. A native outer membrane vesicle vaccine that expresses fHbp variants can potentially elicit protective antibodies against strains from all capsular groups that cause epidemics in the region.

Citing Articles

Factor H binding protein (FHbp): An evaluation of genotypic diversity across serogroups.

Li Z, Murthy A, Hao L, Andrew L, Anderson A Hum Vaccin Immunother. 2024; 20(1):2409502.

PMID: 39387286 PMC: 11469366. DOI: 10.1080/21645515.2024.2409502.

Incidence and Prevention of Invasive Meningococcal Disease in Global Mass Gathering Events.

Razak Muttalif A, Presa J, Haridy H, Gamil A, Serra L, Cane A Infect Dis Ther. 2019; 8(4):569-579.

PMID: 31471813 PMC: 6856249. DOI: 10.1007/s40121-019-00262-9.

Molecular characterization of two sub-family specific monoclonal antibodies to meningococcal Factor H binding protein.

Lo Passo C, Zippilli L, Angiolillo A, Costa I, Pernice I, Galbo R Heliyon. 2018; 4(4):e00591.

PMID: 29644339 PMC: 5889710. DOI: 10.1016/j.heliyon.2018.e00591.

MenB-FHbp Meningococcal Group B Vaccine (Trumenba): A Review in Active Immunization in Individuals Aged ≥ 10 Years.

Shirley M, Taha M Drugs. 2018; 78(2):257-268.

PMID: 29380290 DOI: 10.1007/s40265-018-0869-7.

The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C.

Partridge E, Lujan E, Giuntini S, Vu D, Granoff D Vaccine. 2017; 35(33):4236-4244.

PMID: 28651840 PMC: 5560085. DOI: 10.1016/j.vaccine.2017.06.020.

References

Gagneux S, Wirth T, Hodgson A, Ehrhard I, Morelli G, Kriz P . Clonal groupings in serogroup X Neisseria meningitidis. Emerg Infect Dis. 2002; 8(5):462-6. PMC: 2732495. DOI: 10.3201/eid0805.010227. View

Maiden M, Bygraves J, Feil E, Morelli G, Russell J, Urwin R . Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A. 1998; 95(6):3140-5. PMC: 19708. DOI: 10.1073/pnas.95.6.3140. View

van der Ley P, Steeghs L, Hamstra H, Ten Hove J, Zomer B, van Alphen L . Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun. 2001; 69(10):5981-90. PMC: 98725. DOI: 10.1128/IAI.69.10.5981-5990.2001. View

Masignani V, Comanducci M, Giuliani M, Bambini S, Adu-Bobie J, Arico B . Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003; 197(6):789-99. PMC: 2193853. DOI: 10.1084/jem.20021911. View

Wang J, Caugant D, Li X, Hu X, Poolman J, Crowe B . Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infect Immun. 1992; 60(12):5267-82. PMC: 258306. DOI: 10.1128/iai.60.12.5267-5282.1992. View

Welsch J, Moe G, Rossi R, Adu-Bobie J, Rappuoli R, Granoff D . Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis. 2003; 188(11):1730-40. DOI: 10.1086/379375. View

Oster P, OHallahan J, Aaberge I, Tilman S, Ypma E, Martin D . Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine. 2007; 25(16):3075-9. DOI: 10.1016/j.vaccine.2007.01.023. View

Beernink P, Welsch J, Harrison L, Leipus A, Kaplan S, Granoff D . Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis. 2007; 195(10):1472-9. PMC: 2245893. DOI: 10.1086/514821. View

Holst J . Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum Vaccin. 2007; 3(6):290-4. DOI: 10.4161/hv.4513. View

10.

Koeberling O, Giuntini S, Seubert A, Granoff D . Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol. 2008; 16(2):156-62. PMC: 2643535. DOI: 10.1128/CVI.00403-08. View

11.

Fredriksen J, Rosenqvist E, Wedege E, Bryn K, Bjune G, Froholm L . Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 1991; 14(2):67-79; discussion 79-80. View

12.

Giuliani M, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L . A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A. 2006; 103(29):10834-9. PMC: 2047628. DOI: 10.1073/pnas.0603940103. View

13.

De Groot A, Rappuoli R . Genome-derived vaccines. Expert Rev Vaccines. 2004; 3(1):59-76. DOI: 10.1586/14760584.3.1.59. View

14.

Boisier P, Nicolas P, Djibo S, Taha M, Jeanne I, Mainassara H . Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 2007; 44(5):657-63. DOI: 10.1086/511646. View

15.

Frasch C, van Alphen L, Holst J, Poolman J, Rosenqvist E . Outer membrane protein vesicle vaccines for meningococcal disease. Methods Mol Med. 2011; 66:81-107. DOI: 10.1385/1-59259-148-5:81. View

16.

Welsch J, Ram S, Koeberling O, Granoff D . Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis. 2008; 197(7):1053-61. DOI: 10.1086/528994. View

17.

Koeberling O, Welsch J, Granoff D . Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870. Vaccine. 2006; 25(10):1912-20. DOI: 10.1016/j.vaccine.2006.03.092. View

18.

Taha M, Zarantonelli M, Alonso J, Naess L, Holst J, Feiring B . Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine. 2006; 25(14):2537-8. DOI: 10.1016/j.vaccine.2005.12.059. View

19.

Koumare B, Ouedraogo-Traore R, Sanou I, Yada A, Sow I, Lusamba P . The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine. 2007; 25 Suppl 1:A37-41. DOI: 10.1016/j.vaccine.2007.04.038. View

20.

Beernink P, Leipus A, Granoff D . Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol. 2006; 13(7):758-63. PMC: 1489572. DOI: 10.1128/CVI.00097-06. View